Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Aralez Pharmaceuticals (ARLZ) Stock Price

News articles about Aralez Pharmaceuticals (NASDAQ:ARLZ) have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aralez Pharmaceuticals earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.0606135990206 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the media headlines that may have effected Accern Sentiment’s scoring:

Shares of Aralez Pharmaceuticals (NASDAQ:ARLZ) traded up 5.10% during midday trading on Friday, reaching $1.03. The company had a trading volume of 757,992 shares. Aralez Pharmaceuticals has a one year low of $0.95 and a one year high of $6.80. The company’s market capitalization is $67.82 million. The company has a 50 day moving average of $1.31 and a 200 day moving average of $2.14.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.42) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.01. Aralez Pharmaceuticals had a negative net margin of 122.35% and a negative return on equity of 90.17%. The firm had revenue of $27.62 million for the quarter, compared to analysts’ expectations of $21.37 million. During the same quarter in the previous year, the business earned ($0.27) EPS. The company’s revenue for the quarter was up 119.6% on a year-over-year basis. Analysts predict that Aralez Pharmaceuticals will post ($0.54) EPS for the current fiscal year.

A number of research firms have recently commented on ARLZ. ValuEngine cut Aralez Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Chardan Capital lowered their price target on Aralez Pharmaceuticals from $5.50 to $4.00 and set a “buy” rating for the company in a report on Thursday.

COPYRIGHT VIOLATION WARNING: This report was first reported by BNB Daily and is the sole property of of BNB Daily. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at

In other news, insider Andrew I. Koven sold 161,906 shares of Aralez Pharmaceuticals stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $1.28, for a total value of $207,239.68. Following the transaction, the insider now owns 1,363,695 shares in the company, valued at $1,745,529.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Jason Aryeh sold 388,685 shares of Aralez Pharmaceuticals stock in a transaction dated Tuesday, May 23rd. The stock was sold at an average price of $1.44, for a total value of $559,706.40. Following the completion of the transaction, the director now owns 15,000 shares in the company, valued at approximately $21,600. The disclosure for this sale can be found here. Insiders have sold 569,115 shares of company stock worth $790,719 in the last 90 days. Company insiders own 6.70% of the company’s stock.

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply